Wyeth Premarin Biannual Price Increases To Boost "Cheap" 60[cents] Daily Cost
Executive Summary
Wyeth-Ayerst will adopt a biannual price increase strategy for the hormone replacement therapy Premarin, the company told analysts during its second quarter earnings call July 24.
You may also be interested in...
Premarin Family Sales Stabilize, Wyeth Says; Price Increases Help
Premarin family sales have leveled off since the sharp decline seen in the months following the release of the Women's Health Initiative study, Wyeth reports
Premarin Family Sales Stabilize, Wyeth Says; Price Increases Help
Premarin family sales have leveled off since the sharp decline seen in the months following the release of the Women's Health Initiative study, Wyeth reports
Wyeth Allocates Prempro/Premarin Inventories; Stocking Too High, Firm Says
Wyeth has implemented temporary allocation caps on its conjugated estrogens product line in an effort to reduce inventories in the trade